89581-38-4

Usage

Uses

Used in Pharmaceutical Industry:
Methyl-5-bromo-2 pyrimidine carboxylate is used as a key intermediate in the synthesis of mGlu5 positive allosteric modulators (PAMs) for the development of drugs targeting the metabotropic glutamate receptor 5 (mGlu5). These PAMs have potential therapeutic applications in the treatment of neurological disorders, such as schizophrenia, anxiety, and Fragile X syndrome, due to their ability to modulate the activity of the mGlu5 receptor.
Additionally, Methyl-5-bromo-2 pyrimidine carboxylate can be used as a building block in the design and synthesis of other bioactive molecules, including antiviral, anticancer, and anti-inflammatory agents, owing to its versatile chemical structure and reactivity. Its presence in the pyrimidine ring system allows for the formation of various heterocyclic compounds with potential biological activities, making it a valuable component in the development of novel therapeutic agents.

InChI:InChI=1/C6H5BrN2O2/c1-11-6(10)5-8-2-4(7)3-9-5/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 1013335-78-8 5-bromopyridine-2-carboxylic acid chloride 
• 38275-57-9 5-bromopyrimidine-2-carbonitrile 
• 37131-87-6 5-bromo-2-pyrimidinecarboxylic acid 

Downstream Products

• 38275-60-4 5-bromo-pyrimidine-2-carboxylic acid amide 
• 14080-23-0 2-cyanopyrimidine 
• 88511-48-2 pyrimidine-2-carboxamide 
• 45695-56-5 pyrimidine-2-carboxamidine 
• 90993-49-0 (Z)-N'-hydroxy-pyrimidine-2-carboxamidine 
• 91091-16-6 N-phenyl-pyrimidine-2-carboximidic acid amide 
• 22433-12-1 (5-bromopyrimidine-2-yl)methanol 
• 87362-30-9 5-bromopyrimidine-2-carbohydrazide 
• 1312312-95-0 methyl 5-[4-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)phenyl]-pyrimidine-2-carboxylate 
• 2624136-36-1 methyl 5-(dimethylphosphoryl)pyrimidine-2-carboxylate 
• 1610705-51-5 methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine-2-carboxylate 

Relevant academic research and scientific papers

2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS

The present disclosure provides pharmaceutical compositions comprising 2-arylsulfonamido-N-arylacetamide derivatized Stat3 inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use.

CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, and each of Ra, Rb, R1, R2, R3 and R7 of Formula (I), independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and 15 deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimers Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas (II) and (III), and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

P2X7 MODULATORS

The present invention is directed to a compound of Formula (I) and to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.

ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER

Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.

SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS

The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing, said, inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).